在血管光滑肌细胞中化酶5的失活会加剧大动脉动脉瘤和剖析
Yuyao Feng1,2, Yunfei Xue1, Xiaohang Feng1
1Department of Pathophysiology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, PR China.
The Journal of pathology
|March 27, 2025
概括
大动脉光滑肌细胞中减少的化酶5A (PDE5A) 会使大动脉动脉瘤和剖析 (AAD) 恶化. 恢复PDE5A可以防止AAD,建议在高危患者中谨慎使用PDE5A抑制剂.
科学领域:
- 心血管生物学 心血管生物学
- 血管病理学 血管病理学
- 分子医学是分子医学.
背景情况:
- 大动脉动脉瘤和解剖 (AAD) 是危及生命的血管疾病.
- 基化酶5A (PDE5A) 抑制剂与ADAD风险增加有关.
- 在血管光滑肌细胞 (SMC) 中PDE5A在AAD病变发生过程中的特定作用尚不清楚.
研究的目的:
- 研究SMC特异性PDE5A在大动脉动脉瘤和剖析的发展中的作用.
- 阐明 PDE5A 影响 AAD 的分子机制.
主要方法:
- 使用scRNA-seq,西部涂抹,免疫光和免疫组织化学分析人类和小鼠大动脉组织中PDE5A表达的分析.
- 生产和利用SMC特定的PDE5A淘汰和过度表达的小鼠模型.
- 用高脂肪饮食和Ang II输液诱导AAD小鼠模型,随后进行体内成像和组织学分析.
主要成果:
- 发现PDE5A表达在人类和小鼠AAD组织中被降低,特别是在SMC中.
- 特定于SMC的PDE5A的淘汰或药理抑制加剧了大动脉扩张和弹性质降解,增加了AAD的发生率.
- 在SMC中过度表达PDE5A,在受挑战的小鼠中挽救了AAD表型.
- 从机理上讲,PDE5A缺乏导致了cGMP依赖蛋白激酶 (PKG) 激活的增加,并减少了肌光链 (MLC) 酸化,表明增强了SMC放松.
结论:
- 在SMC中对PDE5A的降低调节或抑制在加剧AAD方面起着致病作用.
- 这种恶化很可能是由强化的cGMP/PKG驱动的大动脉SMC放松的媒介.
- 临床使用PDE5抑制剂在容易患上大动脉疾病的患者中需要谨慎.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
121
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
121
Nitric Oxide Signaling Pathway
4.9K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
4.9K
Vascular Spasm
1.1K
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last...
1.1K
Antihypertensive Drugs: Vasodilators
449
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
449
Antihypertensive Drugs: Action of Calcium Channel Blockers
418
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
418


